Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer

The primary purpose of this study is to determine what proportion of participants will achieve complete pathological response with epirubicin+ cyclophosphamide followed by docetaxel +carboplatin. This will also examine the potential of using signals in the blood (biomarkers) to identify resistance to chemotherapy in Nigerian women with triple negative breast cancer (TNBC). All enrollment to this trial will occur at sites in Nigeria. University of Chicago is serving as coordinating center and will be involved in data analysis.

Trial Details

NCT ID

NCT06291064

Phase

PHASE2

Sponsor

University of Chicago

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

Cyclophosphamide
Epirubicin
Docetaxel
Carboplatin
Breast Surgery
Capecitabine

Locations (sample)

Ikeja, Lagos, Nigeria|6.59651,3.34205
Yaba, Lagos, Nigeria|6.51395,3.37389
Ile-Ife, Osun State, Nigeria|7.4824,4.56032
Ibadan, Oyo State, Nigeria|7.37756,3.90591

Key Eligibility Criteria

Women ages of 18 to 70 years old
Women who are able and willing to read understand and sign an informed consent document
Biopsy-accessible breast tumor of significant size for core needle biopsy/ultrasound measurable (≥ 2cm)
Patients with histologically confirmed carcinoma of the female breast with triple-negative status by immunohistochemistry (IHC). Patients who are l…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →